

**How far are we from WHO HCV Elimination 2030 goals with 10 years of revolutionary treatments?**

Conference of Polish Hepatology Expert’s Group.

**PRELIMINARY PROGRAM-** *Lecturers to be confirmed*

**25.04.2025**

**I: OPENING SESSION:**

**12:25-13:05 Purpose: Highlighting the actual status of Poland on HCV Elimination with a Multistakeholder approach with 6 Polish Stakeholders**

**Opening:**

13:05-13:45 Polish perspective towards HCV elimination

13:45-14:00 *10 Years of Revolutionary HCV Treatment*

 *Status of HCV Elimination Globally & Poland National Elimination Profile - lecturer to be confirmed*

II SESSION: Key Learnings on National Screening Programmes in EUROPE

14:00-14:20 Germany

14:20-14:35 Lithuania - National HCV Screening Program in Lithuania

14:35 -15:35 Introduction to debate: Status of Poland in GP Screening 2025

**15:35–16:15 Debate Panel discussion: How Poland can improve elimination program?**

**16:15-16:30 COFFEE BREAK**

**III SESION: SCREENING STRATEGY FOR INTEGRATING HCV AS A MULTISYSTEMIC DISEASE in Europe**

**16:30-17:15 Purpose:** Position Oncology and Emergency Screening strategies to be implemented for HCV Elimination in Hospitals

17:15-17:35 Spain

**17:35-18:05 Debate Panel discussion: How can we unify our approach to accelerate elimination in Hospital Care System**

**IV SESSION: Key Learnings on HCV Elimination in Prisons in EUROPE**

**Purpose:** Share UK and CZ Prison Programs and discuss how it can be applicable to Poland

18:05-18:20 HCV Management in Prison in UK and PWIDs

18:20-18:40 Prisoners Project - Czech

18:40-18:50 Achievements and Challenges in Prison

**18:50-19:10 Debate Panel discussion: How can we accelerate elimination in Prisons?**

**V SESSION: ROLE of Patient Associations in HCV Elimination**

19:10-19:20 Poland: Non-medical testing – good practice

19:20-19:30 Refuges in Poland

**19:30-19:50 Closing**

**26.04.2025**

**MASLD and liver diseases diagnostics- 15-minute lectures**

**09:00-10:10 I Diagnostics of liver diseases**

09:00-09:15 Is anti-HCV always relible in HCV infection identification

09:15-09:30 How to diagnose MASLD and MASH

09:30-09:45 Monitoring of liver cirrhosis – what to do to be aware of consequences

09:45-10:00 Liver biopsy versus/together with non-invasive tests

10:00-10:10 Discussion

**10:10-11:20 II Rare/not diagnosed liver diseases**

10:10-10:25 PBC – diagnostic and therapeutic perspective- Prof. Michał Kukla

10:25-10:40 HDV – shall we screen all HBV infected patients

10:40-10:55 HCC – how to avoid and treat

10:55-11:10 Hepatic encephalopathy – diagnosis and treatment at different stages of disease

11:10-11:20 Discussion

**11:20-12:45 III MASLD**

11:20-11:35 New nomenclature of steatotic liver disease – impact on everyday clinical practice

11:35-11:50 Risk groups of MASLD and how to screen them

11:50-12:05 Liver steatosis in Primary Care Settings

12:05-12:20 Do we have any treatment for MASLD

12:20-12:35 Future of MASLD specific therapy

12:35-12:45 Discussion